Cargando…

CO50 Efficacy and Safety of Itolizumab for the Treatment of Coronavirus Disease (COVID-19): A Systematic Literature Review

Detalles Bibliográficos
Autores principales:	Gurram, NS, Vagicharla, RB, Rayapureddy, G, Kummari, P, Pulleddula, K, Mir, J, Sharma, S, Tanushree, C, Kohli, IS, Goyal, R, Aggarwal, A, Chakrawarthy, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9747500/ http://dx.doi.org/10.1016/j.jval.2022.09.129

Ejemplares similares

Itolizumab in Psoriasis
por: Srivastava, Ankita
Publicado: (2017)

Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
por: Pai, Ganesh, et al.
Publicado: (2017)

Spotlight on itolizumab in the treatment of psoriasis – current perspectives from India
por: Budamakuntla, Leelavathy, et al.
Publicado: (2019)

Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?
por: Atal, Shubham, et al.
Publicado: (2020)

Treatment of COVID‐19 patients with the anti‐CD6 antibody itolizumab
por: Caballero, Armando, et al.
Publicado: (2020)

Severe bronchospasm following itolizumab infusion in a COVID-19 patient
por: Kumar, Neeraj, et al.
Publicado: (2022)

Adverse drug reactions of itolizumab in COVID-19 patient: A case report
por: Mohammed, Ziauddin, et al.
Publicado: (2022)

T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2017)

A Real-World Study to Assess the Effectiveness of Itolizumab in Patients with Chronic Plaque Psoriasis
por: Parthasaradhi, Anchala, et al.
Publicado: (2017)

Second-degree Heart Block Caused by Itolizumab-induced Infusion Reaction in COVID-19
por: Kumar, Abhyuday, et al.
Publicado: (2021)

Correction: T cell activation and differentiation is modulated by a CD6 domain 1 antibody Itolizumab
por: Bughani, Usha, et al.
Publicado: (2018)

Are We Jumping the Gun with Itolizumab in India? A Situational Analysis from the Pre-COVID Era
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020)

Potential effects of itolizumab treatment on plasma interleukin-6 levels in patients with severe COVID-19
por: Vityala, Yethindra, et al.
Publicado: (2021)

Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions
por: Singh, Vinay
Publicado: (2016)

An Exploratory Study of Itolizumab on the Preservation of Beta Cell Function in Adults with Recent-Onset Type 1 Diabetes
por: Cabrera-Rode, Eduardo, et al.
Publicado: (2022)

Itolizumab/sodium chloride: Second degree heart block secondary to infusion related hypersensitivity reaction: case report
Publicado: (2021)

Itolizumab – a humanized anti-CD6 monoclonal antibody with better side effects profile for the treatment of psoriasis [Corrigendum]
Publicado: (2015)

Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis
por: Menon, Roshni, et al.
Publicado: (2015)

An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
por: Saavedra, Danay, et al.
Publicado: (2020)

Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center
por: Kumari, Poonam, et al.
Publicado: (2021)

A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19
por: Kumar, Suresh, et al.
Publicado: (2021)

Subclinical Hypothyroidism Presenting as Myxedema Coma: Case Report and Literature Review
por: Dolkar, Tsering, et al.
Publicado: (2022)

Recurrent Granulosa Cell Tumor in a Postmenopausal Woman: A Case Report and Literature Review
por: Dolkar, Tsering, et al.
Publicado: (2023)

PB2196: EQUATOR: A PIVOTAL PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ITOLIZUMAB IN COMBINATION WITH CORTICOSTEROIDS FOR THE INITIAL TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE
por: Koreth, J., et al.
Publicado: (2022)

Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019
por: Aggarwal, Gaurav, et al.
Publicado: (2020)

Local Nerve Block in Meralgia Paresthetica - What Does the Evidence Suggests?
por: Chawla, Tanushree, et al.
Publicado: (2023)

Tofersen: Silver Lining or Hyperbole??
por: Chawla, Tanushree, et al.
Publicado: (2023)

Uncommon Bilateral Carotid Artery Dissection in a Farmer: The Perils of Heavy Weight Lifting
por: Sahu, Asha, et al.
Publicado: (2023)

Human pathogen coronaviruses – An overview
por: McFee, R.B.
Publicado: (2020)

The “Collar Tab Sign”–An Atypical MRI Feature in Uremic Encephalopathy
por: Chawla, Tanushree, et al.
Publicado: (2023)

Can imaging impact the coronavirus pandemic?
por: Kohli, Anirudh
Publicado: (2020)

Middle East Respiratory Syndrome (MERS) Coronavirus
por: McFee, R.B.
Publicado: (2020)

Comparative safety and efficacy of tibolone and escitalopram in postmenopausal women
por: Raj, Rajnish, et al.
Publicado: (2021)

Keutel Syndrome, a Review of 50 Years of Literature
por: Cancela, M. Leonor, et al.
Publicado: (2021)

Elective nodal dose of 60 Gy or 50 Gy in head and neck cancers: A matched pair analysis of outcomes and toxicity
por: Murthy, Vedang, et al.
Publicado: (2017)

Assessment of genetic diversity and phylogenetic relationships in Black Pied cattle in the Novosibirsk Region using microsatellite markers
por: Aitnazarov, R.B., et al.
Publicado: (2021)

Clinical features of 50 cases of 2019 novel coronavirus in Bandar Abbas, Iran
por: Jarineshin, Hashem, et al.
Publicado: (2021)

Carrier transport and photoconductivity properties of BN(50)/NiO(50) nanocomposite films
por: Kaur, Manjot, et al.
Publicado: (2023)

Coronavirus Disease 2019: Coronaviruses and Blood Safety
por: Chang, Le, et al.
Publicado: (2020)

Neutron capture on $^{50}$Cr and $^{53}$Cr for criticality safety
por: Guerrero, Carlos, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_iunvmi2atnutcupbbb8odvmgmf